We are live on ! Find out more
BLRX

BioLineRX
BLRX

28 hedge funds and large institutions have $10.3M invested in BioLineRX in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

661% more capital invested

Capital invested by funds: $1.36M → $10.3M (+$8.97M)

14% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 7

0.03% more ownership

Funds ownership: 0% → 0.03% (+0.03%)

0% more funds holding

Funds holding: 28 → 28 (0)

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

Holders
28
Holders Change
–
Holders Change %
0%
% of All Funds
0.48%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
8
Increased
5
Reduced
6
Closed
7
Calls
$22K
Puts
–
Net Calls
+$22K
Net Calls Change
-$27K

Top Buyers

Rank Fund Capital Flow
1
ACM
Altium Capital Management
New York
+$5.92M
2
SM
Sabby Management
Florida
+$4.33M
3
AC
Armistice Capital
New York
+$3.99M
4
AWM
Apollon Wealth Management
South Carolina
+$69.6K
5
VF
Virtu Financial
New York
+$43.6K

Top Sellers

Rank Fund Capital Flow
1
Envestnet Asset Management
Envestnet Asset Management
Illinois
-$30.7K
2
Citadel Advisors
Citadel Advisors
Florida
-$29K
3
GWM
Geneos Wealth Management
Colorado
-$25.6K
4
TNB
Thomasville National Bank
Georgia
-$13K
5
LPL Financial
LPL Financial
California
-$5.71K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
Altium Capital Management
New York
$3.84M +$5.92M +103,732 New
SM
2
Sabby Management
Florida
$2.81M +$4.33M +75,853 New
AC
3
Armistice Capital
New York
$2.59M +$3.99M +69,926 New
PHP
4
Parkman Healthcare Partners
Connecticut
$267K +$4.85K +85 +1%
Morgan Stanley
5
Morgan Stanley
New York
$243K +$14.8K +259 +4%
AWS
6
Atria Wealth Solutions
New York
$96.2K – – –
Renaissance Technologies
7
Renaissance Technologies
New York
$63K +$32.1K +562 +49%
AWM
8
Apollon Wealth Management
South Carolina
$45K +$69.6K +1,220 New
PAM
9
PVG Asset Management
Colorado
$44.3K +$68.3K +1,197 New
LPL Financial
10
LPL Financial
California
$43K -$5.71K -100 -8%
VF
11
Virtu Financial
New York
$43K +$43.6K +764 +196%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$29K – – –
Envestnet Asset Management
13
Envestnet Asset Management
Illinois
$28K -$30.7K -538 -42%
TSS
14
Two Sigma Securities
New York
$28K +$43.4K +760 New
ACM
15
ACT Capital Management
Pennsylvania
$25K – – –
GWM
16
Geneos Wealth Management
Colorado
$21K -$25.6K -448 -43%
CCB
17
Cutter & Co Brokerage
Missouri
$17K – – –
OM
18
Opaleye Management
Massachusetts
$16K – – –
RhumbLine Advisers
19
RhumbLine Advisers
Massachusetts
$16K +$3.59K +63 +17%
SSA
20
Schonfeld Strategic Advisors
New York
$13K -$285 -5 -1%
Creative Planning
21
Creative Planning
Kansas
$13K – – –
UBS Group
22
UBS Group
Switzerland
$12K +$18.3K +320 New
Millennium Management
23
Millennium Management
New York
$12K +$19.1K +335 New
Osaic Holdings
24
Osaic Holdings
Arizona
$10K -$3.99K -70 -21%
Group One Trading
25
Group One Trading
Illinois
$9K – – –
1
2

BLRX Hedge Fund Activity: Q3 2022 in Review

28 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q3 2022, worth a combined $10.3M — up 661% from $1.36M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new BLRX positions and 7 closed out — a net gain of 1 holder — while 5 added to existing stakes and 6 trimmed.

The largest buyer was Altium Capital Management, opening a new position worth an estimated $5.92M. The largest seller was Envestnet Asset Management, cutting an estimated $30.7K.

  • 28 institutional investors held BioLineRX (BLRX) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $10.3M of BioLineRX stock for Q3 2022, up 661% quarter-over-quarter.
  • 8 funds opened new BioLineRX positions in Q3 2022 and 7 closed out, a net change of +1 holder.
  • The largest BioLineRX buyer in Q3 2022 was Altium Capital Management, an estimated $5.92M added.
  • The largest BioLineRX seller in Q3 2022 was Envestnet Asset Management, an estimated $30.7K sold.

Based on aggregated 13F filings for Q3 2022.